75618-41-6

Basic information

• Product Name: 2,3-Dichloro-6-nitrobenzaldehyde
• Synonyms: Benzaldehyde, 2,3-dichloro-6-nitro
• CAS NO: 75618-41-6
• Molecular Formula: C₇H₃Cl₂NO₃
• Molecular Weight: 220.01
• Mol File: 75618-41-6.mol

Chemical Properties

• Melting Point: 86.5℃ (ethanol )
• Appearance: /
• CAS DataBase Reference: 2,3-Dichloro-6-nitrobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Dichloro-6-nitrobenzaldehyde(75618-41-6)
• EPA Substance Registry System: 2,3-Dichloro-6-nitrobenzaldehyde(75618-41-6)

Safety Data

• Hazardous Substances Data: 75618-41-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dichloro-6-nitrobenzaldehyde is used as a reactant in the synthesis of Staurosporinone (K000510) analogues, which are protein kinase C inhibitors of microbial origin. These analogues have potential applications in the development of drugs targeting various diseases, including cancer and other disorders related to protein kinase C activity.
Used in Organic Synthesis:
2,3-Dichloro-6-nitrobenzaldehyde is also used as a building block in the synthesis of other organic compounds, such as dyes, pigments, and polymers. Its unique structure allows for further functionalization and modification, making it a versatile component in the development of new materials and chemical products.

Upstream product

• 6334-18-5 2,3-dichlorobenzylaldehyde 

Downstream Products

• 393078-37-0 2,3-dichloro-6-nitrobenzyl alcohol 
• 70380-51-7 3,4-dichloro-2-hydroxymethylaniline 
• 1372860-85-9 ethyl 2-[(2,3-dichloro-6-nitrobenzyl)amino]isobutyrate hydrochloride 
• 1235447-04-7 3,3-dimethylanagrelide tosylate 
• 1029711-88-3 3,3-dimethylanagrelide 
• 2112-22-3 2,3-dichloro-6-nitrobenzonitrile 
• 6371-39-7 (E)-4,5,4',5'-tetrachloro-1H,1'H-[2,2']biindolylidene-3,3'-dione 
• 99-54-7 3,4-dichloronitrobenzene 

Relevant articles and documents

Preparation method of anagrelide impurities B

The invention discloses a preparation method of anagrelide impurities B. The structure of the anagrelide impurities B is shown in formula I as shown in specification, and is obtained by nitratlon reaction, reduction reaction, halogenating reaction, conden

PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF

The present invention relates to a novel process for producing anagrelide, 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin 2(3H)-one, or certain analogues thereof. The process of the invention also provides improved processes for producing key intermedia

PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF

The present invention relates to a novel process for producing anagrelide, 6,7-dichloro-1,5- dihydroimidazo [2,1-b] quinazolin 2 (3H)-one, or certain analogues thereof. The process of the invention also provides improved processes for producing key interm

PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES

The present invention relates to a novel process for producing quinazoline compounds which are useful in therapy. More specifically, the compounds produced by the process of the invention are useful in the treatment of a number of cardiovascular diseases.

Aminophenyl derivatives as selective androgen receptor modulators

Disclosed herein is a novel class of aminophenyl compounds having the structure: wherein R1 is cyano or nitro and ring A is a bi- or tricyclic bridged heterocycle and to their use as modulators of androgen receptor for the treatment or preventi

METHOD FOR THE PRODUCTION OF ANAGRELIDE HYDROCHLORIDE

Disclosed is a method for producing 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazoline-2(3H)-on hydrochloride (anagrelide hydrochloride). Said method comprises the following steps: a) 2,3-dichlorobenzaldehyde is nitrated to obtain 2,3-dichloro-6-nitrobenzaldehyde; b) 2,3-dichloro-6-nitrobenzaldehyde is reacted with hydroxylamine HCl and acetic anhydride by applying heat so as to obtain 2,3-dichloro-6-nitrobenzonitrile; c) the nitro group of 2,3-dichloro-6-nitrobenzonitrile is reduced to obtain 2,3-dichloro-6-aminobenzonitrile; d) the nitrile group of 2,3-dichloro-6-aminobenzonitrile is reduced to obtain 2,3-dichloro-6-aminobenzylamine dihydrochloride; e) 2,3-dichloro-6-aminobenzylamine dihydrochloride is reacted with i) bromoacetic acid ethyl ester, CH3CN, and triethylamine; and ii) BrCN to obtain (2-amino-5,6-dichloro-4H-quinazoline-3-yl) acetic acid ethyl ester; f) (2-amino-5,6-dichloro-4H-quinazoline-3-yl) acetic acid ethyl ester is reacted in cycloalkylation conditions to obtain 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazoline-2(3H)-on; and g) 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazoline-2(3H)-on is reacted with HCl to obtain anagrelide hydrochloride.

Method for the manufacture of anagrelide

Methods are provided for making Anagrelide base from 2,3-dichlorobenzaldehyde. A method is also provided for making an intermediate compound ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine from 2,3-dichlorobenzaldehyde and for reducing the glycine compound using either SnCl2 or a specially defined catalyst. A cyclization method to form Anagrelide base from the corresponding iminoquinazoline compound is further provided.

2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof

The compound 2-amino-5,6-dichloro-3,4-dihydroquinazoline has been found to have enhanced platelet count reducing properties. Also provided are methods for synthetically making the compound and a method of reducing the platelet count in a patient by administering to the patient a platelet reducing effective amount of the compound preferably together with a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which contains the above compound as the active ingredient together with pharmaceutically acceptable excipients.